Immunome, Inc. (NASDAQ:IMNM) CTO Philip Tsai Acquires 12,300 Shares

Immunome, Inc. (NASDAQ:IMNM) CTO Philip Tsai bought 12,300 shares of the firm’s stock in a transaction on Monday, March 24th. The stock was purchased at an average price of $8.42 per share, with a total value of $103,566.00. Following the completion of the acquisition, the chief technology officer now owns 33,300 shares of the company’s stock, valued at approximately $280,386. This trade represents a 58.57 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Immunome Stock Performance

Immunome stock opened at $6.95 on Wednesday. Immunome, Inc. has a 52 week low of $6.94 and a 52 week high of $26.70. The firm has a market capitalization of $604.31 million, a PE ratio of -0.86 and a beta of 1.93. The business’s 50-day simple moving average is $9.67 and its 200-day simple moving average is $11.44.

Immunome (NASDAQ:IMNM) last issued its quarterly earnings results on Wednesday, March 19th. The company reported ($0.84) EPS for the quarter, missing the consensus estimate of ($0.68) by ($0.16). Immunome had a negative return on equity of 48.63% and a negative net margin of 3,014.59%. The business had revenue of $2.74 million during the quarter, compared to the consensus estimate of $3.07 million. Research analysts forecast that Immunome, Inc. will post -2.21 earnings per share for the current year.

Analysts Set New Price Targets

Several analysts have recently commented on IMNM shares. Guggenheim decreased their target price on Immunome from $35.00 to $25.00 and set a “buy” rating for the company in a research report on Thursday, March 20th. Wedbush reaffirmed an “outperform” rating and set a $33.00 price objective on shares of Immunome in a research report on Thursday, March 20th. Stephens restated an “overweight” rating and issued a $30.00 target price on shares of Immunome in a research note on Thursday, March 20th. Finally, Lifesci Capital assumed coverage on Immunome in a research note on Tuesday, March 11th. They set an “outperform” rating and a $20.00 price target for the company. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $25.50.

Hedge Funds Weigh In On Immunome

A number of institutional investors and hedge funds have recently bought and sold shares of IMNM. Wellington Management Group LLP lifted its stake in shares of Immunome by 3.5% in the fourth quarter. Wellington Management Group LLP now owns 145,564 shares of the company’s stock valued at $1,546,000 after buying an additional 4,874 shares during the period. Wealth Enhancement Advisory Services LLC boosted its position in Immunome by 5.1% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 41,505 shares of the company’s stock valued at $441,000 after buying an additional 2,005 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in Immunome by 32.7% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 58,193 shares of the company’s stock worth $618,000 after acquiring an additional 14,328 shares during the last quarter. Woodline Partners LP grew its holdings in shares of Immunome by 6.1% during the fourth quarter. Woodline Partners LP now owns 980,925 shares of the company’s stock worth $10,417,000 after purchasing an additional 56,533 shares during the last quarter. Finally, Two Sigma Advisers LP acquired a new stake in Immunome in the 4th quarter valued at about $512,000. Institutional investors own 44.58% of the company’s stock.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.